162 related articles for article (PubMed ID: 21535879)
1. The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients.
Xishan Z; Guangyu A; Yuguang S; Hongmei Z
J Exp Clin Cancer Res; 2011 May; 30(1):47. PubMed ID: 21535879
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-9 was involved in the immuno-modulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients.
Zhu XS; Shi W; An GY; Zhang HM; Song YG; Li YB
Chin Med J (Engl); 2011 Aug; 124(16):2423-30. PubMed ID: 21933581
[TBL] [Abstract][Full Text] [Related]
3. Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it.
Xishan Z; Xinna Z; Baoxin H; Jun R
Cancer Immunol Immunother; 2013 Apr; 62(4):689-703. PubMed ID: 23180012
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.
Li Q; Wu Y; Fang S; Wang L; Qi H; Zhang Y; Zhang J; Li W
Cancer Gene Ther; 2015 May; 22(5):227-37. PubMed ID: 25837664
[TBL] [Abstract][Full Text] [Related]
5. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics.
Fang B; Zheng C; Liao L; Han Q; Sun Z; Jiang X; Zhao RC
Blood; 2005 Apr; 105(7):2733-40. PubMed ID: 15591120
[TBL] [Abstract][Full Text] [Related]
6. Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients.
Han Q; Sun Z; Liu L; Chen B; Cao Y; Li K; Zhao RC
Leuk Res; 2007 Nov; 31(11):1469-78. PubMed ID: 17360037
[TBL] [Abstract][Full Text] [Related]
7. TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts.
Zhu X; Wang L; Zhang B; Li J; Dou X; Zhao RC
J Biochem; 2011 Apr; 149(4):405-14. PubMed ID: 21288887
[TBL] [Abstract][Full Text] [Related]
8. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP; Fang BJ; Wei XD; Zheng S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
[TBL] [Abstract][Full Text] [Related]
9. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Aljedai A; Buckle AM; Hiwarkar P; Syed F
PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
[TBL] [Abstract][Full Text] [Related]
10. Hemangioblastic characteristics of cancer stem cells in chronic myeloid leukemia.
Xishan Z; Xu Z; Lawei Y; Gang L
Clin Lab; 2012; 58(7-8):607-13. PubMed ID: 22997961
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant.
Carrara RC; Orellana MD; Fontes AM; Palma PV; Kashima S; Mendes MR; Coutinho MA; Voltarelli JC; Covas DT
Braz J Med Biol Res; 2007 Jan; 40(1):57-67. PubMed ID: 17224997
[TBL] [Abstract][Full Text] [Related]
12. The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia.
Zhao ZG; Xu W; Sun L; Li WM; Li QB; Zou P
Eur J Cancer; 2012 Aug; 48(12):1884-95. PubMed ID: 22129888
[TBL] [Abstract][Full Text] [Related]
13. C/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
Hayashi Y; Hirai H; Kamio N; Yao H; Yoshioka S; Miura Y; Ashihara E; Fujiyama Y; Tenen DG; Maekawa T
Leukemia; 2013 Mar; 27(3):619-28. PubMed ID: 22948537
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive properties of mesenchymal stem cells derived from bone marrow of patients with chronic myeloid leukemia.
Zhao ZG; Li WM; Chen ZC; You Y; Zou P
Immunol Invest; 2008; 37(7):726-39. PubMed ID: 18821219
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.
Jootar S; Pornprasertsud N; Petvises S; Rerkamnuaychoke B; Disthabanchong S; Pakakasama S; Ungkanont A; Hongeng S
Leuk Res; 2006 Dec; 30(12):1493-8. PubMed ID: 16839603
[TBL] [Abstract][Full Text] [Related]
17. Assessment of bone marrow mesenchymal stem cell biological characteristics and support hemotopoiesis function in patients with chronic myeloid leukemia.
Zhao Z; Tang X; You Y; Li W; Liu F; Zou P
Leuk Res; 2006 Aug; 30(8):993-1003. PubMed ID: 16448696
[TBL] [Abstract][Full Text] [Related]
18. Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells.
Moore S; Haylock DN; Lévesque JP; McDiarmid LA; Samels LM; To LB; Simmons PJ; Hughes TP
Blood; 1998 Oct; 92(7):2461-70. PubMed ID: 9746786
[TBL] [Abstract][Full Text] [Related]
19. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL1-positive microvesicles malignantly transform human bone marrow mesenchymal stem cells in vitro.
Fu FF; Zhu XJ; Wang HX; Zhang LM; Yuan GL; Chen ZC; Li QB
Acta Pharmacol Sin; 2017 Nov; 38(11):1475-1485. PubMed ID: 28836580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
